The United States Court of Appeals for the Federal Circuit has granted a motion to temporarily enjoin the generic launch by Teva and Apotex of Hetlioz.
CMS proposes that issuers of standardized plan options must place all covered generic drugs in the standardized plan options’ generic drug cost-sharing tier.